TrialHaematologica2023

Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients.

Spyridoula Vasileiou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.